A new study of health insurance records of more than 400,000 U.S. diabetics found no higher risk of heart attacks with GlaxoSmithKline'spill Avandia when compared with other oral diabetes drugs, the drugmaker said in documents made public Thursday.
The study also showed no higher rate of coronary revascularization procedures, such as bypass surgery, in patients who took Avandia, the company said.
Glaxo funded the study, which was done by researchers at i3 Drug Safety, a division of health information company Ingenix.
The findings were included in a summary Glaxo provided to the Food and Drug Administration, which is holding an advisory panel meeting on Monday to evaluate Avandia's heart risks.